1. Home
  2. GNFT vs STXS Comparison

GNFT vs STXS Comparison

Compare GNFT & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNFT
  • STXS
  • Stock Information
  • Founded
  • GNFT 1999
  • STXS 1990
  • Country
  • GNFT France
  • STXS United States
  • Employees
  • GNFT N/A
  • STXS N/A
  • Industry
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • GNFT Health Care
  • STXS Health Care
  • Exchange
  • GNFT Nasdaq
  • STXS Nasdaq
  • Market Cap
  • GNFT 214.5M
  • STXS 151.3M
  • IPO Year
  • GNFT 2019
  • STXS 2004
  • Fundamental
  • Price
  • GNFT N/A
  • STXS $2.20
  • Analyst Decision
  • GNFT Strong Buy
  • STXS
  • Analyst Count
  • GNFT 1
  • STXS 0
  • Target Price
  • GNFT $13.00
  • STXS N/A
  • AVG Volume (30 Days)
  • GNFT 4.2K
  • STXS 288.7K
  • Earning Date
  • GNFT 04-24-2025
  • STXS 08-11-2025
  • Dividend Yield
  • GNFT N/A
  • STXS N/A
  • EPS Growth
  • GNFT N/A
  • STXS N/A
  • EPS
  • GNFT 0.03
  • STXS N/A
  • Revenue
  • GNFT $73,187,701.00
  • STXS $27,510,000.00
  • Revenue This Year
  • GNFT $15.98
  • STXS $25.90
  • Revenue Next Year
  • GNFT N/A
  • STXS $60.57
  • P/E Ratio
  • GNFT $125.14
  • STXS N/A
  • Revenue Growth
  • GNFT 105.01
  • STXS 1.50
  • 52 Week Low
  • GNFT $2.55
  • STXS $1.54
  • 52 Week High
  • GNFT $6.42
  • STXS $2.72
  • Technical
  • Relative Strength Index (RSI)
  • GNFT 46.56
  • STXS 52.17
  • Support Level
  • GNFT $3.61
  • STXS $2.08
  • Resistance Level
  • GNFT $3.95
  • STXS $2.36
  • Average True Range (ATR)
  • GNFT 0.14
  • STXS 0.12
  • MACD
  • GNFT -0.01
  • STXS -0.01
  • Stochastic Oscillator
  • GNFT 50.64
  • STXS 55.56

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: